Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis

Cancer Science

Volumn 95, Issue 12, 2004, Pages 955-961

  Iwaki, Hideaki ^a   Kageyama, Susumu ^a   Isono, Takahiro ^a   Wakabayashi, Yoshihiko ^a   Okada, Yusaku ^a   Yoshimura, Koji ^b   Terai, Akito ^b   Arai, Yoichi ^c   Iwamura, Hiroshi ^d   Kawakita, Mutsushi ^d   Yoshiki, Tatsuhiro ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CATECHOL METHYLTRANSFERASE; GAMMA SYNUCLEIN; ISOENZYME; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CALCULATION; CANCER GRADING; CANCER STAGING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPATHOLOGY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEIN URINE LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOLUBILITY; TUMOR VOLUME; URINALYSIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CALRETICULIN; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GAMMA-SYNUCLEIN; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NERVE TISSUE PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SYNUCLEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 19944429012     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03183.x     Document Type: Article

References (21)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. The Foundation for Promotion of Cancer Research. Cancer Statistics in Japan 2003. Available from: URL: http://www.ncc.go.jp/en/statistics/index.html (The last date of access was January 5th 2004).
3. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27: 1-13.
4. Prout GR Jr, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 1992; 148: 1413-9.
5. Brown FM. Urine cytology. It is still the gold standard for screening? Urol Clin North Am 2000; 27: 25-37.
6. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003; 169: 1975-82.
7. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001; 165: 600-11.
8. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y, Yoshiki T. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004; 50: 857-66.
9. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, Shi YE. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997; 57: 759-64.
10. Lavedan C. The synuclein family. Genome Res 1998; 8 871-80.
11. Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res 1999; 59 742-7.
12. Bruening W, Giasson BI, Klem-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 2000; 88: 2154-63.
13. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003; 63: 664-73.
14. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999; 59: 4870-5.
15. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O-methyl-transferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001; 61: 6716-22.
16. Lee BC, Cha K, Avraham S, Avraham HK. Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol 2004; 24: 847-51.
17. Isono T, Tanaka T, Kageyama S, Yoshiki T. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 2002; 48: 2187-94.
18. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52: 398-402.
19. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997; 57: 778-83.
20. Lueking A, Horn M, Eickhoff H, Bussow K, Lehrach H, Walter G, Protein microarrays for gene expression and antibody screening. Anal Biochem 1999; 270: 103-11.
21. Vilkner T, Janasek D, Manz A. Micro total analysis systems. Recent developments. Anal Chem 2004; 76: 3373-85.